NORGINE VENTURES COMPLETES 5 MILLION FINANCING WITH SUPERSONIC IMAGINE SA

10 January 2014

London. 10 January 2014. Norgine Ventures today announced that it has provided financing of €5 million to SuperSonic Imagine SA. The financing was realised in form of private bonds with warrants.

Norgine Ventures’ investment will enable SuperSonic Imagine to accelerate further technological development and commercial expansion in the US and in Asia. Norgine Ventures is a business entity of Norgine, an independent pan-European specialty pharmaceutical company.

SuperSonic Imagine designs and commercialises the Aixplorer^®, an innovative ultrasound system that utilises patented ShearWave™ Elastography technology to image and measure tissue stiffness in real time. Tissue stiffness is an important parameter in the determination of malignancies. The Aixplorer® is the only ultrasound system in the world to offer, not only, B-mode and Doppler imaging but also, innovations such as ShearWave™ Elastography and UltraFast™ Doppler (a unique tool that combines Color Doppler and Pulsed Wave Doppler to increase exam time and patient throughput). Aixplorer® covers all diagnostic, clinical applications such as: breast, thyroid, abdomen, liver, musculo-skeletal, prostate, gynaecology and obstetrics.

SuperSonic Imagine was founded in 2005 in Aix-en-Provence. Since inception, the company secured a number of government research grants and raised four financing rounds from private investors, including Edmond de Rothschild Investment Partners (EdRIP), Auriga Partners, Omnes Capital, NBGI Ventures, Bioam, Mérieux Développement, Wellington Partners, Innobio, IXO Private Equity, IRDI Midi-Pyrénées, Alto Invest, Kuwait Life Sciences Company, Canon and BPIFrance (Banque Publique d'Investissement).

Today, SuperSonic Imagine has a direct sales team in four countries and a distribution network in over 50 countries worldwide, and holds the exclusive rights, titles and interests to 30 international patents and submissions in diagnostic imaging and therapy applications.

Peter Stein, Norgine Ventures CEO, said: “Norgine Ventures’ investment in SuperSonic Imagine demonstrates our commitment to grow valuable assets that can drive innovation and improve healthcare outcomes”. He added: “SuperSonic Imagine’s technology can revolutionise the diagnosis of cancer and provide economic value to healthcare systems, enabling provision of the right treatment, to the right patient, at the right time.”

Jacques Souquet, SSI CEO, said : “We are thankful for the collaboration with Norgine Ventures as it will enable us to increase both our commercial footprint and pursue other clinical innovations leveraging the breakthrough technology we have developed. Our contribution to the field of imaging has already had an impact in domains like breast cancer and prostate. We believe that with the market launch of a new generation of hepatitis C drugs, Aixplorer® can also make a difference to clinicians and patients in this therapeutic area, by improving assessment of the benefit of the drug and avoiding unnecessary biopsies.”

-Ends-

Notes to Editors

For further information please contact

Julien Michaux, Norgine Ventures, +44 (0)1895826600, jmichaux@norgine.com

Media

Isabelle Jouin, Norgine Corporate Communications, +44 (0)1895453643, ijouin@norgine.com

Rachelle Michaels, Norgine Corporate Communications, +44 (0)1895453607, rmichaels@norgine.com

About Norgine and Norgine Ventures

Norgine is a leading independent European specialty pharmaceutical company that has been established for over 100 years and has a presence in all major European markets. In 2013, Norgine’s net product sales were c.€267 million and the company employs over 1,000 people. Norgine’s focus is the development and marketing of pharmaceutical products that address significant unmet clinical needs in therapeutic areas such as gastroenterology, hepatology, critical and supportive care. Norgine owns a manufacturing and development site in Hengoed, UK and a manufacturing site in Dreux, France. For more information: www.norgine.com

Norgine Ventures was started in 2012 to diversify Norgine’s activities and to foster innovation in the healthcare sector. Norgine Ventures provides debt and debt-like financing to innovative, fast growing companies in the fields of healthcare and life sciences, in Europe and the US. For more information: www.norgineventures.com

NORGINE and the sail logo are trademarks of the Norgine group of companies.

About SuperSonic Imagine SA

Founded in 2005 and based in Aix-en-Provence, France, SuperSonic Imagine is an innovative, multinational medical imaging company dedicated to developing a revolutionary ultrasound system: the Aixplorer®. This system leverages a unique technology that enables the user to detect, characterize and, in the future, treat palpable and non-palpable masses. Learn more at www.supersonicimagine.com

Cookie Policy

Last update: 1 August 2023

What are cookies?

Cookies are small data files that websites download to a user’s computer, phone or tablet. Most web browsers automatically accept cookies. They help website providers, for example, to recognise a user that has visited a website previously. Further details on the cookies used on this Website and their purposes are set out below.

Helping you navigate the Website in the most easy way possible
Assisting in registering for our events, login and your ability to provide feedback
Analysing site usage (how many users visited a specific page for example)
Analysing the use of our products, services or applications
Assisting with our promotional and marketing efforts (including behavioural advertising)
Offering content of third parties (such as social media content)

Detailed information about each cookie can be found in the appropriate cookie category section of the banner as well as in the section below.

Cookie Category Description

STRICTLY NECESSARY COOKIES

The strictly necessary cookies help make a website usable by enabling basic functions like page navigation and access to secure areas of the website. These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You may be able to decline these cookies through your browser, but necessary parts of the site will not then work. These cookies do not store any personally identifiable information.

Detailed list of Strictly Necessary Cookies

First- and Third-party Cookies	Name	Provider	Purpose	Retention
Third Party	moove_gdpr_popup	mooveagency.com	Records cookie settings. For user preferences only. No external interaction	1 year

FUNCTIONAL COOKIES

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly.

Detailed list of Functional Cookies

PERFORMANCE COOKIES

These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site.

Detailed list of Performance Cookies

First- and Third-party Cookies	Name	Provider	Purpose	Retention
Third Party	_ga_	google.com	Record visitors cookie choice.	400 days
Third Party	_gat_gtag_	google.com	Records tracking code data	1 minute
Third Party	_ga	google.com	Calculates visitor, session and campaign data and also keeps track of site usage.	400 days
Third Party	_gid	google.com	Registers a unique ID that is used to generate statistical data on how the visitor uses the website.	1 day

MARKETING COOKIES

These cookies are used to track our visitors’ browsing habits. They can be used to build up a profile of search and/or browsing history for every visitor. Identifiable or unique data is collected to show relevant/personalized marketing content to each user. The information that uniquely identifies users’ browsers and internet devices is used to display targeted advertising and/or share this data with third parties for the same purpose.

Detailed list of Marketing Cookies

Refusing cookies

You do not have to accept cookies, but without accepting them you may experience reduced Site functionality. You can manage your preferences regarding cookies and other tracking technologies and revoke your consent in the banner. You can withdraw your consent at any time. If you would like more information about deleting, disabling and blocking cookies, please visit the website: https://knowcookies.com and check the “manage cookies” and “webmasters guide” sections.

Updating our Cookie Policy

There is a possibility that we will update our cookie policy on this website in accordance with legal and technical requirements, therefore we recommend that you read this policy occasionally so that you are adequately informed about how and for what we use cookies.

Contact

If you have any questions about this Cookie Policy or the collection, processing and disclosure of your personal data and your data protection rights, please see our Privacy Policy.